AERI - Aerie Pharmaceuticals Non-GAAP EPS of -$0.27 beats by $0.16 revenue of $36.1M beats by $0.8M
- Aerie Pharmaceuticals press release ( NASDAQ: AERI ): Q3 Non-GAAP EPS of -$0.27 beats by $0.16 .
- Revenue of $36.1M (+23.2% Y/Y) beats by $0.8M .
- Cash, cash equivalents, and investments were $172.5 million as of September 30, 2022 compared to $139.8 million as of December 31, 2021.
- During the third quarter of 2022, our net cash used in operating activities was $11.4 million and total net change in cash, cash equivalents, and investments (total net cash used) was $11.9 million.
For further details see:
Aerie Pharmaceuticals Non-GAAP EPS of -$0.27 beats by $0.16, revenue of $36.1M beats by $0.8M